$DYAI Dyadic Advances Collaboration with Israel In
Post# of 78
(Total Views: 202)
Posted On: 02/21/2024 8:43:11 AM
$DYAI Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
https://www.globenewswire.com/news-release/20...tions.html
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company"
(NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.
Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR. The IIBR will enhance Dyadic's C1 cell lines using proprietary gene sequences to improve biomanufacturing of recombinant vaccines and neutralizing agents, including targeted antigens and monoclonal antibodies. The joint effort is focused on addressing emerging diseases through global commercial out-licensing initiatives to increase access and affordability of vaccines and antibodies to patients.
Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic. Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats. The collaboration aims to expedite the development of safe, protective, and effective vaccines and treatments against various biothreat agents, including toxins, viruses, and bacteria. These products can be manufactured more rapidly, in larger quantities and at a lower cost using Dyadic's C1 protein expression platform.
https://www.globenewswire.com/news-release/20...tions.html
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company"
(NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives. Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR. The IIBR will enhance Dyadic's C1 cell lines using proprietary gene sequences to improve biomanufacturing of recombinant vaccines and neutralizing agents, including targeted antigens and monoclonal antibodies. The joint effort is focused on addressing emerging diseases through global commercial out-licensing initiatives to increase access and affordability of vaccines and antibodies to patients.
Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic. Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats. The collaboration aims to expedite the development of safe, protective, and effective vaccines and treatments against various biothreat agents, including toxins, viruses, and bacteria. These products can be manufactured more rapidly, in larger quantities and at a lower cost using Dyadic's C1 protein expression platform.
(0)
(0)